Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Applovin Corporation (APP) vs Moderna, Inc. (MRNA) Price & Performance

Applovin CorporationTrade
Moderna, Inc.Trade

Price performance (Past 24H)

Key statistics

Applovin Corporation vs Moderna, Inc. — how do they compare? Applovin Corporation trades at $319.81 (market cap $113.45B), while Moderna, Inc. trades at $60.67 (market cap $23.88B). The key difference: Applovin Corporation is far larger — about 4.8× Moderna, Inc.'s market cap, and Moderna, Inc. is trading nearer its 52-week high, Applovin Corporation nearer its low. Which is the better fit depends on your goals.

APPMRNA
Market Cap
$113.45B$23.88B
Sector
TechnologyHealth
52-Week High
$733.60$81.80
52-Week Low
$318.68$22.36
Enterprise Value
$113.91B$20.03B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Applovin Corporation

AppLovin (APP) trades at $346.80, down 3.32% amid a bearish technical outlook despite strong fundamentals. The stock faces selling pressure after Q2 revenue missed expectations, though it maintains exceptional profitability with 64.58% net margins and 53% YoY revenue growth. Analyst consensus remains bullish with an $569.60 price target, but technical indicators show 18 sell signals versus 2 buys.

The stock presents a growth-at-a-reasonable-price opportunity post-selloff, trading at 26x P/E with 80% analyst buy ratings. Key risks include execution volatility in AI-driven ad pricing and high valuation multiples. Upside depends on Q3 results meeting elevated guidance of 47% growth.

Moderna, Inc.

Moderna (MRNA) stock trades at $59.17, up 9.86% recently, with a bullish technical signal and strong institutional buying interest. The company's Q2 2026 earnings beat expectations, and the FDA approval of its mRNA flu vaccine, mFLUSIVA, for adults 50+ marks a key post-pandemic milestone. However, fundamentals show declining revenue from $18.9B in 2022 to $1.9B in 2025 and persistent net losses, with a negative net income margin of -142.58% in 2025.

The outlook hinges on pipeline execution; while new vaccine approvals and cost-cutting efforts offer growth potential, the stock faces risks from high valuation multiples and ongoing profitability challenges. Analyst consensus is cautious with a $54.33 price target below the current price, reflecting mixed sentiment amid transitional phase uncertainties.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Applovin Corporation

AppLovin provides a software platform for mobile app developers to market, monetize, and analyze their apps. Its AI-powered tools help developers grow their business by connecting them with global advertising networks.

Read more on APP

About Moderna, Inc.

Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.

Read more on MRNA